Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 28 August 2018 Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy Non-regulated information 31 July 2018 Study Abstract on Performance of Idylla™ RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US) Non-regulated information 17 July 2018 Biocartis launches innovative Idylla™ MSI Assay Idylla™ MSI Assay further strengthens Biocartis’ test menu and offers opportunities to enter the immuno-oncology testing market Non-regulated information 27 June 2018 Study Reviewing 2,500 Performed Idylla™ Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods Non-regulated information 29 May 2018 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 28 May 2018 Study Demonstrates Ability of Idylla™ EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests Non-regulated information 17 May 2018 Two Performance Studies on Idylla™ MSI Biomarkers Selected for Publication at ASCO Conference Non-regulated information 11 May 2018 Results of the annual shareholders’ meeting held on 11 May 2018 Regulated information 26 April 2018 Biocartis Q1 2018 Business Update Regulated information 10 April 2018 Invitation to Annual Shareholders’ Meeting Biocartis Group NV to propose new board composition Regulated information Pagination First page « First Previous page ‹‹ … Page 18 Page 19 Page 20 Page 21 Current page 22 Page 23 Page 24 Page 25 Page 26 … Next page ›› Last page Last »